Skip to main content
. 2019 Sep 20;39(9):BSR20190986. doi: 10.1042/BSR20190986

Figure 4. MiR-31 targets and inhibits Bach2 expression.

Figure 4

(A,B) qRT-PCR results of miR-31 (A) and IL-22 (B) in Th22−CD4+ T cells and Th22+CD4+ T cells from CHD patients. (C) Schematic of the putative miR-31 target site in human Bach2 3′-UTR and the seven mutated nucleotides are colored red. Luciferase report assay delineated a reduction in luciferase activity of Bach2-WT reporter after introduction of miR-31 in HEK293T cells. (D) qRT-PCR and Western blotting analysis of Bach2 in CD4+ T cells transfected with miR-31 mimic, miR-31 inhibitor, and corresponding controls. Data were presented as mean ± SD (n=3). *P<0.05 vs Th22−CD4+ T cells or non-CHD; #P<0.05 vs mimic NC; &P<0.05 vs inhibitor NC.